Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136766 | 0.85 | CA2 (0.43) | CA2CA1PTGS2PTGS1CYP1A2 | |
| SCHEMBL723478 | 0.85 | CA2 (0.40) | CA2CA1PTGS2PTGS1CYP1A2 | |
| SCHEMBL27969314 | 0.84 | HPGD (0.38) | CA2CA1PTGS2PTGS1ALDH1A1 | |
| SCHEMBL724696 | 0.81 | NR5A2 (0.39) | CA2CA1PTGS2PTGS1GAA | |
| SCHEMBL721937 | 0.81 | PTGS1 (0.40) | CA2CA1PTGS2PTGS1CYP1A2 | |
| SCHEMBL10136781 | 0.78 | CA2 (0.41) | CA2CA1PTGS2PTGS1CYP1A2 | |
| SCHEMBL18060588 | 0.77 | CA2 (0.37) | CA2CA1PTGS2PTGS1CYP1A2 | |
| SCHEMBL18060590 | 0.76 | CA1 (0.36) | CA2CA1PTGS2PTGS1CYP1A2 | |
| SCHEMBL1015675 | 0.75 | NTRK1 (0.58) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL722566 | 0.75 | PTGS2 (0.42) | CA2CA1PTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103917526-A | Pyrimidine carboxamide derivatives | APAC PHARMACEUTICAL LLC | 2014-07-09 | — | — | CN | claimed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| CN-103917526-A | Pyrimidine carboxamide derivatives | APAC PHARMACEUTICAL LLC | 2014-07-09 | — | — | CN | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | NOD1, IL1B, IRAK1 | CA2 2402/4885CA1 2949/4885PTGS2 155/4885 |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | NOD1, IL1B, IRAK1 | CA2 2402/4885CA1 2949/4885PTGS2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.